Eugene

Biogen has entered into an agreement to acquire Nightstar Therapeutics (NST), a clinical-stage gene- therapy company based in London, which is focused on adeno-associated virus (AAV) treatments for inherited retinal…

Abpro, a Woburn, Massachusetts-based biotechnology company developing antibody therapeutics, and NJCTTQ, a pharmaceutical company based in Nanjing, China, have entered into an agreement to develop multiple bispecific antibody therapies in…

Ipsen, a pharmaceutical company headquartered in Paris, and Clementia Pharmaceuticals, a biopharmaceutical company headquartered in Montreal, have entered into an agreement for Ipsen to acquire Clementia for approximately $1.31 billion.…

Morphic Therapeutic, a biotechnology company developing oral integrin therapies, based in Waltham, Massachusetts, has entered into a research and development (R&D) collaboration with Janssen Biotech for over $725 million, if…

AbbVie and Voyager Therapeutics, a clinical-stage gene therapy company based in Cambridge, Massachusetts, have formed a strategic collaboration and option agreement to develop and commercialize vectorized antibodies for treating Parkinson’s…

Roche and Spark Therapeutics, a commercial gene-therapy company based in Philadelphia, have entered into a definitive merger agreement for Roche to fully acquire Spark Therapeutics for $4.3 billion or $114.50…

Merck & Co. and Immune Design, a late-stage immunotherapy company headquartered in Seattle, Washington, have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Immune Design…